Fredun Pharmaceuticals strengthens veterinary business, targets growing livestock market

Fredun Pharmaceuticals Limited (BSE: 539730), a provider of veterinary pharmaceuticals, is expanding its footprint in the large animal healthcare sector with the launch of two new products under its Freossi veterinary products division. Known for its expertise in companion animal care, the company is now introducing Freossi Tone+ and Freossi Power, aimed at improving lactation, mobility, and joint health in livestock.

The Fredun Pharmaceuticals expansion into large animal veterinary products is a strategic move to strengthen its presence in the growing livestock healthcare segment. With a strong reputation in pet nutrition and veterinary formulations, the company is leveraging its expertise to address critical health challenges in cattle, horses, and other large animals.

New Product Offerings: Focus on Livestock Health and Performance

Fredun Pharmaceuticals is bringing evidence-based solutions to large animal healthcare with its latest offerings.

Freossi Tone+: A Scientifically Formulated Lactation Support Solution

Freossi Tone+ is designed to enhance milk yield, improve lactation cycles, and support overall bone and muscle health. The formulation includes Microcrystalline Hydroxyapatite Complex (MCHC), proteins, collagens, and a proprietary herbal extract blend. Ideal for cows, buffaloes, goats, and horses, the product aims to address common challenges in dairy farming, such as irregular lactation and postpartum health issues.

Key benefits include:

• Higher milk production and improved milk fat content
• Prevention of milk fever and postpartum haemorrhage
• Enhanced skeletal and muscular health

Freossi Power: A Performance Enhancer for Mobility and Joint Health

Freossi Power is designed to support joint health and reduce inflammation in large animals. The formulation includes MCHC, Glucosamine Sulphate USP, and Methylsulfonylmethane (MSM), known for their role in cartilage regeneration and joint flexibility. Targeted at horses, bulls, ponies, and cattle, Freossi Power is expected to become a staple in large animal healthcare.

Key benefits include:

• Relief from joint stiffness, lameness, and inflammation
• Reduction in osteoarthritis-related pain
• Increased stamina and range of motion

Strategic Expansion to Strengthen Veterinary Portfolio

Commenting on the Fredun Pharmaceuticals expansion, Managing Director Fredun Medhora emphasized the company’s commitment to providing innovative and science-backed veterinary solutions. He highlighted that Freossi veterinary products would cater to the needs of livestock owners, reinforcing the company’s position as a key player in large animal healthcare.

The launch of these products is part of a broader strategy to transition beyond pet care and establish a comprehensive range of livestock health solutions. Fredun Pharmaceuticals is actively developing additional products to address evolving industry needs and strengthen its market position in veterinary healthcare.

Market Position and Future Growth Prospects

With the global livestock industry growing rapidly, demand for effective animal healthcare solutions is rising. The Fredun Pharmaceuticals expansion into large animal healthcare aligns with this trend, offering scientifically validated solutions that enhance productivity and animal welfare. The company’s expertise in MCHC-based formulations, backed by six decades of research, positions it well for sustained growth in the veterinary sector.

Additionally, Fredun Pharmaceuticals’ expansion efforts are expected to contribute to revenue diversification, complementing its existing portfolio of pharmaceuticals, nutraceuticals, and cosmeceuticals. The company primarily exports to Africa, Southeast Asia, CIS countries, and Latin America, and the introduction of Freossi veterinary products is expected to strengthen its presence in these markets.

Investor Sentiment and Market Response

Fredun Pharmaceuticals’ stock (BSE: 539730) has seen increased interest following this strategic move. Investors are evaluating the potential financial impact of the company’s expansion into large animal healthcare, given the growing market demand for veterinary pharmaceuticals. If the Freossi veterinary products gain traction, it could contribute positively to Fredun Pharmaceuticals’ revenue growth and profitability.

With its entry into large animal healthcare, Fredun Pharmaceuticals is reinforcing its reputation as an innovator in veterinary medicine. The launch of Freossi veterinary products, including Freossi Tone+ and Freossi Power, marks a significant step toward addressing key health concerns in livestock while strengthening the company’s position in the global veterinary healthcare industry.